Vitality Watch

Dossier clinicaltrials trial early 11-sep-2026
Small or early-phase human trial or pilot study

Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia

Key claim: A multi-center, randomized, double-blind, placebo-controlled Phase 1/2 trial is evaluating the efficacy and safety of investigational agent EN001 in patients with sarcopenia.

Abstract

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Sarcopenia

Why this matters

Sarcopenia remains a core healthspan target with no approved pharmacological therapy, so any investigational agent entering controlled human testing expands the small pool of drug candidates alongside myostatin/activin inhibitors, SARMs, and mitochondria-targeted muscle therapeutics. A Phase 1/2 RCT establishes EN001 on the human-evidence ladder but produces no efficacy readout yet — it is a trial-in-progress signal, not an outcome.

Source

Link

Briefing card

Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Stage: trial early · clinicaltrials · 11-sep-2026

If you are tracking pharmacological options for sarcopenia, EN001 is now in early human testing but has no efficacy or safety results yet.

A multi-center, randomized, double-blind, placebo-controlled Phase 1/2 trial is evaluating the efficacy and safety of investigational agent EN001 in patients with sarcopenia.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07808905

build build 880 · 2bcef25 · 2026-11-18